IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
February 20, 2024 09:15 ET
|
IR-Med, Inc.
Incidence of pressure injuries reduced by 50% during the study periodAs a decision support device, PressureSafe, can support early detection of pressure injuries, potentially setting a new standard of...
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
February 13, 2024 09:15 ET
|
IR-Med, Inc.
Final results to be reported from a study conducted at two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest in Israel PressureSafe, for...
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
December 07, 2023 09:15 ET
|
IR-Med, Inc.
The Granted patent covers IR-MED’s PressureSafe™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S. annually...
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
October 04, 2023 16:05 ET
|
IR-Med, Inc.
Mr. Di-Cori’s vast healthcare experience includes President of LifeWatch Technologies, a developer of technologies that help physicians detect symptoms before they become major health problems Rosh...
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
September 26, 2023 09:00 ET
|
IR-Med, Inc.
Study to address the substantial challenge of healthcare inequality in the early detection of pressure injuries in people of dark skin tonesPressureSafe, a skin-color agnostic decision support device,...
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
September 13, 2023 09:15 ET
|
IR-Med, Inc.
Served as Chief FDA Counsel for Revlon and Johnson & Johnson, as a Board Member at Johnson & Johnson Development Corporation, that company’s strategic venture capital division, and as patent...
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
August 21, 2023 09:15 ET
|
IR-Med, Inc.
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform...
IR-MED’s AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
July 17, 2023 09:15 ET
|
IR-Med, Inc.
IR-MED to file for FDA approval Q4 2023 with U.S. market launch expected in H1 20242.5 million patients develop pressure injuries and 60,000 die annually as a direct result; $26.8 billion is spent...
IR-MED Honors Juneteenth with Commitment to Healthcare Equality: PressureSafe Device Sees Beneath the Skin to Address Inequality in Pressure Injuries
June 12, 2023 09:15 ET
|
IR-Med, Inc.
Early detection of pressure injuries can be challenging for minority populations due to the current method of visual inspectionPatients with dark skin tones suffered more than twice as much as those...
IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device
June 07, 2023 09:28 ET
|
IR-Med, Inc.
Innovative executive driving positive outcomes and profitability, Dr. Eschenbacher is focused on addressing healthcare access and equityThrough early, non-invasive detection of pressure injuries,...